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Available online 25 May 2016Adolescent males' HPV vaccine initiation and completion in the United States is far below the Healthy People
2020 goal of 80% 3-dose completion among boys. In 2012, less than 7% of males ages 13–17 years had completed
the 3-dose series. The Diffusion of Innovations framework guided this investigation of factors related to early
adoption of HPV vaccination amongmale adolescents. Provider-validated data from the 2012 National Immuni-
zation Survey-Teen (NIS-Teen) for male adolescents ages 13–17 years were analyzed via a multivariable Poisson
regression to estimate prevalence ratios for factors associated with HPV vaccine initiation and completion. Ado-
lescent males who are Hispanic and those who are up to date on other recommended adolescent vaccinations
were most likely to complete the HPV vaccine. Public health interventions are needed to improve low HPV vac-
cination rates among adolescentmales in the United States. Description of early adopters of the HPV vaccine pro-
vides historical context of HPV vaccination acceptance that is needed to inform the design of targeted vaccination
interventions to prevent negative HPV-associated outcomes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
HPV vaccine
Adolescent
Young adult
Immunization
NIS-Teen1. Introduction
In 2009, an estimated 13,446 human papillomavirus (HPV)-
associated cancers were diagnosed among men in the United States
(US) (Chaturvedi et al., 2011), including oropharyngeal (78.2%), anal
(14.4%), and penile (7.4%) cancers (Jemal et al., 2013). HPV-associated
cancers are increasing in incidence; for example, as of 2011 approxi-
mately 70% of cancers of the oropharynx were linked to oral HPV infec-
tion (Chaturvedi et al., 2011). The increase in oropharyngeal cancers has
been attributed to oral infection of high-risk (oncogenic) HPV type 16,
the prevalence of which is estimated to be 1.6% among men aged 14
to 69 years (Gillison et al., 2012). In addition, it is estimated that approx-
imately 250,000 cases of HPV-related genital warts occur annually in
the US among sexually active males (Hoy et al., 2009; Anon., 2011).
However, there is no routine screening for HPV-associated morbid-
ities amongmales, leaving HPV vaccination as the best prevention strat-
egy for these cancers and genitalwarts. TheHPV vaccine, recommended, University of Utah, 2000 Circle
ka), Qian.Ding@hsc.utah.edu
Warner@hci.utah.edu
her).
. This is an open access article underby the Advisory Committee on Immunization Practices (ACIP) for boys
ages 11–21 in 2011, (Anon., 2011) may be effective in reducing oral
HPV infections and anal pre-cancer associated with HPV (Giuliano
et al., 2011; Herrero et al., 2013; Palefsky et al., 2011). For example,
Herrero et al. demonstrated that four years after women were random-
ized to receive the HPV vaccine or a control vaccine, women who re-
ceived the HPV vaccine had signiﬁcantly fewer infections with oral
HPV (Herrero et al., 2013). Although the HPV vaccine is not currently
approved for prevention of oropharyngeal cancer, it is possible that
the protection against oral HPV infection that was observed in vaccinat-
ed women will also extend to vaccinated men. A vaccine that protects
against oral HPV and HPV-related anal pre-cancerous lesions may in
turn reduce the incidence of associated HPV oropharyngeal, anal, and
other cancers.
As of 2014, the Healthy People 2020 HPV target for vaccination cov-
erage is now 80% 3-dose-completion for males aged 13–15 years
(Anon., 2014a). In 2010–2011, theﬁrst year that National Immunization
Survey-Teen (NIS-Teen) data is available, barriers to HPV vaccination
included lack of information and lack of provider recommendation
(Reiter et al., 2013). Despite efforts to improve HPV vaccination, the
most recent data from 2014 indicate that male completion of HPV vac-
cination is at 21.6%, (Anon., 2012a; Anon., 2014b) far below Healthy
People 2020 goals. Moreover, within the ﬁrst year after ACIP recom-
mended HPV vaccination, national HPV vaccine initiation was lowerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2007 (Anon., 2007, 2012a).
To reach the national Healthy People 2020 goal of 80% vaccination
coverage among adolescentmales, research is needed to identify factors
that are associated with HPV vaccination among adolescent boys.
Knowledge of demographic or other factors that relate to early adop-
tion of the HPV vaccine can provide historical context that informs
the design of future interventions to increase receipt of the HPV vac-
cine among boys in the US. Using Rogers' Diffusion of Innovations
(DOI) theory (Rogers, 1983a) for interpreting adoption of the HPV
vaccine enhances our understanding of how vaccine innovations dif-
fuse throughout social systems. This study was guided by DOI, which
posits that populations can be segregated into different segments
based on their willingness to adopt a particular innovation that
ranges from innovators and early adopters to late majority and lag-
gards. This paper aimed to identify factors that were associated
with early adoption of HPV vaccination among adolescent boys. Ac-
cording to the DOI, we expected early adopters to have higher social
status (e.g., higher education, being above poverty level, majority
race/ethnicity, privately insured) (Rogers, 1983b).
2. Methods
The NIS-Teen is a cross-sectional national survey conducted annual-
ly using random digit dialing to sample parents of eligible adolescents
regarding vaccination in the US (Anon., 2008-2014). Upon obtaining
parental consent, adolescents' healthcare providers are contacted to
validate vaccination records. Provider-validated data from the 2012
National Immunization Survey-Teen for male adolescents ages
13–17 years (N= 10,141) were analyzed using survey sample weight-
ed statistics (Anon., 2012b) which adjust for non-response and reﬂect
post stratiﬁcation adjustments to reﬂect the control totals fromnational
data from the National Center for Health Statistics (Anon., 2013a). Ade-
quate provider-veriﬁed vaccination data was available for 23.6% of cel-
lular and 55.2% of landline respondents. Provider-phase sampling
weights for both landline and cell-phone samples in the US proper
were used to produce dual-frame point estimates and corresponding
95% conﬁdence intervals. Frequency counts and survey-weighted per-
centages were reported for the entire US boys subgroup. A survey
weighted multivariable Poisson regression was ﬁtted to assess the im-
pact of predictor variables (mother's education, poverty status, ethnici-
ty/race, adolescent's age, source of health insurance, facility type, and
receipt of other adolescent vaccinations) and reported as an adjusted
prevalence ratio with 95% CI. All predictor variables were clinically im-
portant and were included in the multivariable analysis regardless of
their statistical signiﬁcance. Participants with complete information
for all factors in ourmultivariate analysiswere included. Amultivariable
sensitivity analysis compared factors related to males completing three
doses of theHPV vaccine among thosewhohad aminimumof 24weeks
between receipt of the ﬁrst dose of the HPV vaccine and the date of the
interview. All tests were two-sided comparisons in STATA version 13.1.
The University of Utah Institutional Review Board considers analysis of
publicly available data, the NIS-Teen, exempt.
3. Results
3.1. Demographic and healthcare characteristics of male adolescents
A total of 10,141 adolescent boys with vaccination provider-re-
ported vaccination records were included in the analysis. Of these,
2050 (20.8%) had initiated and 655 (6.8%) had completed the HPV
vaccine series. In Table 1 mothers of the boys were mostly aged
≥35, had received some of or completed a college education, and
were married. Adolescents were primarily living above poverty
level, Non-Hispanic White, and had health insurance through a
parent's employment or union.3.2. Multivariable analysis of factors predicting HPV vaccine completion
among male adolescents
In Table 2, respondentswhosemothers had some college, but no col-
lege degree, were less likely to initiate theHPV vaccine series than those
whose mothers had less than 12 years of education (PR = 0.78, 95%
CI = 0.62–0.99). Non-Hispanic Whites and those with unclassiﬁed eth-
nicities listed as ‘Other’were less likely to initiate the HPV vaccine series
than Hispanic boys (PR = 0.66, 95% CI = 0.55–0.80; PR = 0.73, 95%
CI = 0.56–0.96). For HPV vaccine completion, Non-Hispanic Whites
were still less likely than Hispanics to complete (PR = 0.50, 95% CI =
0.38–0.77). Non-Hispanic Blacks were also less likely to complete HPV
vaccination than Hispanics (PR= 0.55, 95%= 0.36–0.83). No statistical
differences were observed for Other ethnicities. Consistent with the re-
sults observed in the descriptive analysis, adolescent boyswho received
their health insurance through a source other than a parent's employer
or union were more likely to have both initiated (PR = 1.24, 95% CI =
1.02–1.51) and completed the HPV vaccine (PR = 1.55, 95% CI =
1.05–2.28) than boys who had received insurance through a parent's
employer or union. A similar percentage of boyswho received insurance
through a parent's employer or union reported that their provider had
recommended the HPV vaccine compared to those who did not have
this type of insurance (29.2% vs. 26.8%, data not shown).
Receipt of other adolescent vaccinationswas the strongest predictor
of the likelihood ofHPV vaccine initiation and completion. Thosewith at
least one dose of seasonal inﬂuenza vaccination in the past three years
were more likely to initiate HPV vaccination (PR = 1.77, 95% CI =
1.54–2.05) and to complete HPV vaccination (PR = 3.20, 95% CI =
2.37–4.33) than those without inﬂuenza vaccination. Adolescents with
at least one dose of TDAP vaccination ages 10–13 yearsweremore likely
to complete HPV vaccination (PR = 1.61, 95% CI = 1.16–2.25) than
thosewho had not received TDAP. Adolescents with at least oneMenin-
gitis vaccination were also more likely to initiate HPV vaccination than
those without a Meningitis vaccination (PR = 4.98, 95% CI =
3.53–7.00), and were also more likely to complete HPV vaccination
than those without a Meningitis vaccination (PR = 5.55, 95% CI =
2.82–10.91).
Multivariable models were used to compare factors related tomales
completing three doses of the HPV vaccine among those who had at
least 24 weeks between the receipt of the ﬁrst dose of the HPV vaccine
and the date of the interview. Source of health insurance andmeningitis
vaccination were no longer signiﬁcantly associated with 3-dose com-
pletion within the recommended time frame (data not shown).
4. Discussion
Increasing HPV vaccination coverage among adolescent males is a
public health priority. Herein we identiﬁed factors associated with
early adoption of HPV vaccination among adolescent boys from the
2012 NIS-Teen to inform interventional programs and policies that are
effectively targeted to increase HPV vaccination among males. Accord-
ing to DOI, early adopters have higher social status, education, incomes,
and are willing to take risks (Rogers, 1983b). However, male early
adopters of the HPV vaccine do not appear to mirror the DOI early
adopter proﬁle and in fact tend to have opposite characteristics
(e.g., public health insurance, lower income & education). This impor-
tant difference in the proﬁle of early adopters is unexpected, but has im-
plications for designing interventions that appropriately target
individuals who are slower to uptake the HPV vaccine.
In our analysis, HPV vaccination among boys differed by racial/eth-
nic group, in that Hispanic teens were more likely to be vaccinated
than non-Hispanic teens. Similar to previous research, this ﬁnding re-
ﬂects varying levels of support for HPV vaccination by racial/ethnic
groups. Attitudes regarding vaccines generally, and the HPV vaccine
speciﬁcally, may be more positive among Hispanic parents compared
to non-Hispanic parents (Kornfeld et al., 2013). This ﬁnding mirrors
Table 1
Demographic and healthcare characteristics of male adolescents in the United Statesa,b, NIS-Teen 2012 (N = 10141).
Characteristics Total N
(%b)
No vaccination N
(col. %b)
HPV Initiation (≥1 dose)c N
(col. %b)
HPV Completion (≥3 doses)d N
(col. %b)
Total, n (row %b) 10,141 8091 (79.2) 2050 (20.8) 655 (6.8)
Age (Mother/Parent)
≤34 years 763 (9.9) 562 (9.1) 201 (13.3) 66 (13.6)
35 years b age ≤ 44 years 4102 (47.3) 3285 (46.8) 817 (49.4) 234 (47.8)
≥45 years 5276 (42.7) 4244 (44.2) 1032 (37.3) 355 (38.7)
Education (Mother)
b12 years 969 (13.8) 969 (11.5) 281 (22.7) 87 (26.8)
12 years 1941 (25.7) 1941 (25.8) 380 (25.2) 115 (21.0)
N12 years (some college) 2829 (25.6) 2829 (26.9) 473 (20.5) 143 (20.5)
College graduate 4402 (35.0) 4402 (35.9) 916 (31.7) 310 (31.7)
Poverty statuse
Above poverty (N$75k) 4474 (34.4) 3597 (36.0) 877 (27.9) 280 (25.6)
Above poverty (≤$75k) 3714 (39.7) 3065 (41.0) 649 (34.4) 203 (33.7)
Below poverty 1621 (26.0) 1161 (22.9) 460 (37.7) 151 (40.7)
Missing, n (%) 332 (3.27)
Marital status of mother
Married 7526 (65.1) 6116 (66.1) 1410 (61.4) 467 (66.0)
Other 2615 (34.9) 1975 (33.9) 640 (38.6) 188 (34.0)
Ethnicity/Race of teens
Hispanic 1321 (21.7) 943 (18.7) 378 (33.0) 140 (41.0)
Non-Hispanic White only 6872 (55.7) 5719 (59.6) 1153 (40.6) 376 (37.5)
Non-Hispanic Black only 1029 (14.0) 734 (13.1) 295 (17.3) 72 (11.1)
Other 919 (8.7) 695 (8.6) 224 (9.0) 67 (10.4)
Age in years of selected teen
13 years old 2050 (19.8) 1655 (20.2) 395 (18.6) 125 (19.4)
14 years old 2135 (20.0) 1672 (19.7) 463 (21.4) 130 (17.4)
15 years old 2032 (21.4) 1612 (21.4) 420 (21.5) 132 (25.4)
16 years old 1984 (19.3) 1585 (19.3) 399 (19.6) 130 (17.0)
17 years old 1940 (19.4) 1567 (19.5) 373 (18.9) 138 (20.8)
Source of health insurance for teens
Provided through employment or union 6627 (56.4) 5448 (59.3) 1179 (45.1) 371 (42.2)
Not Provided through employment or union 3426 (43.6) 2577 (40.7) 849 (54.9) 276 (57.8)
Missing, n (%) 88 (0.87)
Facility type for teen's providers
All public facilities 1357 (14.8) 1125 (14.8) 232 (14.5) 67 (14.0)
All hospital facilities 931 (7.9) 711 (8.2) 220 (6.8) 65 (5.4)
All private facilities 4790 (52.9) 3814 (52.9) 976 (52.8) 320 (54.7)
Mixed/Other 2684 (24.5) 2137 (24.1) 547 (25.9) 179 (26.0)
Missing, n (%) 379 (3.74)
Do teen's providers order vaccination from state/local health department
All providers 6828 (66.2) 5363 (64.6) 1464 (72.3) 467 (71.7)
Some but possibly not all 1416 (12.3) 1139 (12.2) 277 (12.6) 100 (13.4)
No providers 1043 (12.3) 891 (13.2) 152 (8.7) 43 (9.0)
Don't know 823 (9.2) 666 (10.0) 157 (6.3) 45 (5.9)
Missing, n (%) 32 (0.32)
Inﬂuenza vaccinationf
Yes 4258 (39.3) 2956 (33.8) 1302 (60.0) 464 (74.6)
No 5883 (60.7) 5135 (66.2) 748 (40.0) 191 (25.4)
TDAP vaccinationg
Yes 6681 (63.8) 5155 (62.1) 1526 (70.0) 518 (76.0)
No 3460 (36.3) 2936 (37.9) 524 (30.0) 137 (24.0)
Meningitis vaccinationh
Yes 7527 (74.5) 5593 (69.4) 1934 (94.1) 630 (95.6)
No 2614 (25.5) 2498 (30.6) 116 (5.9) 25 (4.4)
a Male adolescents with adequately complete provider-reported immunization records in the 2012 NIS-Teen survey were included. U.S. Virgin Islands was excluded.
b Weighted percentages from Dual-Frame Sampling Weights.
c HPV initiation includes those who had received at least 1 dose of the HPV vaccine.
d HPV completion includes those who had received at least 3 doses of the HPV vaccine.
e Adolescents were classiﬁed as below federal poverty level if their total family income was less than the federal poverty level speciﬁed for the applicable family size and number of
children aged b18 years.
f Adolescent has taken at least one dose of seasonal inﬂuenza vaccination in the past three years.
g Adolescent has taken at least one dose of TDAP only vaccination since age 10 years old and before 13 years old.
h Adolescent has taken at least one dose of Meningitis vaccination.
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lence of vaccination compared to non-Hispanic Whites, meaning that
approaches for improving other adolescent vaccinations may be useful
for improving HPV vaccination as well.
Additionally, boys who received health insurance through their
parent's employer or union were less likely to have been vaccinated as
compared to those who did not, which may reveal differences in HPV
vaccination distribution patterns in government-funded healthcaresettings or among the uninsured as compared to private insurers. For
example, individuals with public health insurance (e.g., Children's
Health Insurance Program, Medicaid) may be eligible for low- or no-
cost vaccinations, andmay also receive ﬁnancial assistance for complet-
ing the HPV vaccine that individuals with employer or union sponsored
insurance may lack (e.g., Vaccines for Children Program).
In 1996, TDAP booster vaccination was recommended for adoles-
cents at ages 11–12 to harmonize with the vaccination schedule for
Table 2
Multivariable analysis of factors predicting HPV vaccine Initiation and Completion among male adolescents, NIS-Teen 2012 (N= 9376).
HPV initiation HPV completion
Adjusted vaccination
coveragea % (95%CI)
Adjusted prevalence
ratio (95%CI)
Adjusted vaccination
coveragea % (95%CI)
Adjusted prevalence
ratio (95%CI)
Age (Mother/Parent)
≤34 years 23.6 (18.6, 28.7) Reference 7.1 (4.5, 9.7) Reference
35 years b age ≤ 44 years 20.2 (18.0, 22.3) 0.85 (0.67, 1.08) 6.1 (4.8, 7.4) 0.86 (0.56, 1.31)
≥45 years 19.6 (17.4, 21.7) 0.83 (0.65, 1.06) 6.9 (5.4, 8.4) 0.97 (0.62, 1.52)
Education (Mother)
b12 years 22.6 (18.5, 26.7) Reference 6.9 (4.6, 9.3) Reference
12 years 18.5 (15.6, 21.4) 0.82 (0.65, 1.03) 5.3 (3.7, 6.8) 0.76(0.51, 1.14)
N12 years (some college) 17.7 (15.1, 20.3) 0.78 (0.62, 0.99) 5.9 (4.2, 7.6) 0.85(0.55, 1.33)
College graduate 22.7 (19.6, 25.9) 1.00 (0.78, 1.29) 7.8 (5.7, 9.9) 1.12(0.70, 1.80)
Poverty status e
Above poverty (N$75k) 18.8 (15.8, 21.7) Reference 5.3 (3.9, 6.7) Reference
Above poverty (≤$75k) 18.9 (16.5, 21.3) 1.01 (0.83, 1.22) 6.3 (4.8, 7.7) 1.19(0.85, 1.67)
Below poverty 23.6 (19.8, 27.5) 1.26 (0.96, 1.65) 8.0 (5.8, 10.2) 1.51 (0.97, 2.37)
Marital status of mother
Married 20.2 (18.1, 22.2) Reference 6.6 (5.4, 7.8) Reference
Other 20.6 (18.1, 23.2) 1.02 (0.87, 1.20) 6.3 (4.8, 7.8) 0.95 (0.70, 1.30)
Ethnicity/Race of teens
Hispanic 25.6 (21.7, 29.5) Reference 9.4 (6.9, 11.8) Reference
Non-Hispanic White only 17.0 (15.2, 18.7) 0.66 (0.55, 0.80) 5.1 (4.0, 6.1) 0.50 (0.38, 0.77)
Non-Hispanic Black only 23.4 (19.2, 27.7) 0.92 (0.72, 1.16) 5.1 (3.3, 6.9) 0.55 (0.36, 0.83)
Other 18.8 (14.5, 23.1) 0.73 (0.56, 0.96) 8.1 (4.8, 11.3) 0.86 (0.54, 1.38)
Age in years of selected teen
13 years old 18.8 (15.9, 21.7) Reference 5.4 (3.9, 6.9) Reference
14 years old 22.3 (18.7, 25.8) 1.19 (0.96, 1.46) 5.7 (3.8, 7.7) 1.06 (0.69, 1.63)
15 years old 20.1 (17.0, 23.3) 1.07 (0.87, 1.33) 7.4 (5.2, 9.7) 1.38 (0.91, 2.07)
16 years old 21.2 (18.1, 24.4) 1.13 (0.92, 1.40) 6.8 (4.8, 8.7) 1.25 (0.83, 1.87)
17 years old 19.4 (15.9, 22.9) 1.03 (0.82, 1.30) 7.6 (5.4, 9.7) 1.40 (0.95, 2.05)
Source of health insurance for teens
Provided through employment or union 18.2 (15.9, 20.5) Reference 5.2 (3.9, 6.5) Reference
Not Provided through employment or union 22.6 (20.0, 25.2) 1.24 (1.02, 1.51) 8.0 (6.2, 9.8) 1.55 (1.05, 2.28)
Facility type for teen's providers
All public facilities 19.6 (15.3, 23.9) Reference 5.6 (3.3, 8.0) Reference
All hospital facilities 18.3 (13.9, 22.7) 0.93 (0.68, 1.29) 4.2 (2.4, 5.9) 0.74 (0.41, 1.33)
All private facilities 19.6 (17.5, 21.7) 1.00 (0.78, 1.28) 6.5 (5.2, 7.7) 1.15 (0.72, 1.84)
Mixed/Other 23.2 (20.3, 26.1) 1.18 (0.92, 1.52) 7.8 (5.7, 9.9) 1.38 (0.85, 2.26)
Do teen's providers order vaccination from state/local health department
All providers 21.2 (19.4, 22.9) Reference 6.7 (5.6, 7.8) Reference
Some but possibly not all 19.5 (15.4, 23.7) 0.92 (0.74, 1.15) 5.7 (3.6, 7.8) 0.86 (0.57, 1.28)
No providers 18.0 (13.6, 22.5) 0.85 (0.66, 1.11) 6.0 (3.0, 9.0) 0.89 (0.53, 1.50)
Don't know 16.7 (12.1, 21.3) 0.79 (0.59, 1.05) 6.5 (3.1, 9.9) 0.97 (0.56, 1.67)
Inﬂuenza vaccinationb
Yes 26.9 (24.6, 29.2) 1.77 (1.52, 2.05) 10.3 (8.7, 12.0) 3.20 (2.37, 4.33)
No 15.2 (13.3, 17.1) Reference 3.2 (2.4, 4.1) Reference
TDAP vaccinationc
Yes 20.2 (18.4, 21.9) 0.97 (0.82, 1.15) 7.3 (6.2, 8.5) 1.61 (1.16, 2.25)
No 20.8 (17.7, 23.9) Reference 4.6 (3.2, 5.9) Reference
Meningitis vaccinationd
Yes 24.7 (22.7, 26.6) 4.98 (3.53, 7.00) 7.5 (6.5, 8.6) 5.55 (2.82, 10.91)
No 5.0 (3.3, 6.6) Reference 1.4 (0.5, 2.3) Reference
a Multivariable Poisson regression with all variables are included in the model simultaneously. There were 765 (7.54%) subjects excluded due to missing information.
b Adolescent has taken at least one dose of seasonal inﬂuenza vaccination in the past three years.
c Adolescent has taken at least one dose of TDAP only vaccination since age 10 years old and before 13 years old.
d Adolescent has taken at least one dose of Meningitis vaccination.
e Adolescents were classiﬁed as below federal poverty level if their total family income was less than the federal poverty level speciﬁed for the applicable family size and number of
children aged b18 years.
101D. Kepka et al. / Preventive Medicine Reports 4 (2016) 98–102other adolescent vaccines (e.g. Meningitis), (Anon., 1996, 2006) the
same ages as HPV vaccination is now recommended. Over the next
two decades, TDAP vaccination consistently increased in prevalence.
In 2012, NIS-Teen data for TDAP reﬂected that 84.6% of adolescents
ages 11–18 had received TDAP vaccination (Anon., 2013b). Our results
show that 63.8% of adolescent boys had received a TDAP vaccination
at the recommended ages of 11–12 years. Efforts to improve and sustain
high TDAP vaccination have been successful and may elucidate oppor-
tunities to improve HPV vaccination.
Finally, receipt of other adolescent vaccinations, particularly
meningitis, was strongly associated with HPV vaccine initiation and
completion among boys. The discrepancy between the level of HPV
vaccination and that of other recommended adolescent vaccineshighlights missed opportunities. Considering that receipt of other
adolescent immunizations by age 18, such as TDAP, is above the
Healthy People 2020 targets of 80%, (Anon., 2012a) it is evident
that there exist opportunities to initiate HPV vaccination that are
currently underutilized. The 2012–2013 President's Cancer Panel Re-
port on HPV vaccination identiﬁed reducingmissed opportunities for
HPV vaccination as the ﬁrst goal for accelerating HPV vaccination in the
US (Anon., 2014c). Interventions that couple the HPV vaccine with
other recommended adolescent immunizations are needed. Additional-
ly, future research that explores how provider and patient level factors
relate to low HPV vaccination receipt among boys is needed.
There are limitations of this study. After weighting adjustments,
bias from non-response, errors in vaccination status, and differential
102 D. Kepka et al. / Preventive Medicine Reports 4 (2016) 98–102sampling coverage may persist. Given that all independent variables
were included in the multivariate model based on their clinical rele-
vance, there may still be some unmeasured confounding.
5. Conclusions
This study highlights certain demographic factors that are associated
with receipt of HPV vaccination among adolescent boys. Additionally,
our results indicate a need to study the effectiveness of healthcare
provider education on HPV vaccination rates. Healthcare providers
should be encouraged to make strong recommendations for the receipt
of HPV vaccination, and to consider pairing the initiation of the HPV
vaccine with the administration of other recommended adolescent
immunizations.
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